Chávez-Piña AE, Favari L, Castañeda-Hernández G

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 141-147
Archivo PDF: 132.25 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Boltze K, Brendler O, Jacobi H, Optiz W, Raddatz S, Seidel PR, Volbrecht D. Chemical structure and anti-inflammatory activity in the group of substituted indole-3 acetic acids. Arzneimittelforschung 1980; 30: 1314–25.

2. Jacobi H, Dell HD. On the pharmacodynamics of acemetacin. Arzneimittelforschung 1980; 30: 1348–62.

3. Bori-Segura G, Torres A, Herrera LE, Olguín J. Efficacy and tolerability of acemetacin, a non-steroidal anti-inflammatory drug, in Mexican patients: result of the ETAPAM study. Proc West Pharmacol Soc 2002; 45: 104–7.

4. Chou CT, Tsai YY. A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis. Int J Clin Pharmacol Res 2002; 22: 1–6.

5. Jones RW, Collins AJ, Notarianni LJ, Sedman E. The comparative pharmacokinetic of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol 1991; 31: 543–45.

6. Dell HD, Doersing M, Jacobi H, Kamp R. Biochemical studies on Acemetacin experimental test in animals. Arzneimittelforschung 1980; 30(II): 1371-83.

7. Surborg H. Comparative metabolic studies on 14C-labelled acemetacin and indomethacin in rats. Arzneimittelforschung 1980; 30(II): 1384-91.

8. Dell HD, Doersing M, Fischer W, Jacobi H, Kamp R, Köhler G, Schöllnhammer G. Metabolism and pharmacokinetics of acemetacin in man. Arzneimittelforschung 1980; 30(II): 1391-98.

9. Li DM, Lu WL, Wang XQ, Wang JC, Zhang H, Zhan RJ, Wang GL, et al. Pharmacokinetics of indomethacin, a metabolite of acemetacin, following a single dose and multiple doses administered as acemetacin sustained-release tablets in healthy male volunteers. Journal of Health Science 2005; 51(3): 308-16.

10. Chávez-Piña AE, McKnight W, Dicay M, Castañeda-Hernández G, Wallace JL. Mechanism underlying the anti-inflammatory activity and gastric safety of acemetacin. Br J Pharmacol 2007; 152(6): 930-38.

11. Chávez-Piña AE, Vong L, McKnight W, Dicay M, Zanardo RC, Ortiz MI, Castañeda-Hernández G, Wallace JL. Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety. Br J Pharmacol 2008; 155(6):857-64.

12. Boobis AR, Brodie MJ, Kahn GC, Fletcher DR, Saunders JH, Davies DS. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Phamacol 1980; 9(1):11-19.

13. Favari L, Castañeda-Hernández G, Hoyo-Vadillo C. Pharmacokinetics and pharmacodynamics of naproxen in acute experimental hepatitis. Arzneimittelforschung 1993; 43(6): 675-9.

14. Rivera-Espinosa L, Muriel P, Ordaz-Gallo M, Perez-Urizar J, Palma-Aguirre A, Castaneda-Hernandez G. Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat. Ann Hepatol 2003; 2: 175–81.

15. Reyes-Gordillo K, Muriel P, Castañeda-Hernández G, Favari L. Pharmacokinetic of diclofenac in rats intoxicated with CCl4 and in the regenerating liver. Biopharm Drug Dispos 2007; 28:415-22.

16. Doshi J, Luisada-Opper A, Leevy CM. Microsomal pentobarbital hydroxylase activity in acute viral hepatitis. Proc Soc Exp Biol Med 1972; 140(2): 492-95.

17. Gibaldi M, Boyes RN, Feldman S. Influence of first-pass effect on availability of drugs on oral administration. J Pharm Sci 1971; 60(9):1338-40.

18. Norma Oficial Mexicana NOM-062-ZOO-1999. http://www.fmvz.unam.mx/fmvz/principal/archivos/062ZOO.PDF

19. Glossman M, Neville DM. Glutamyl transferase in kidney brush border membranas. FEBS Lett 1972; 19: 340-44.

20. Reitman S, Frankel S. A colorimetric method for determination of serum oxaloacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56-63.

21. Mourelle M, Villalón C, Amezcua JL. Protective effect of colchicine on acute liver damage induced by carbon tetrachloride. J Hepatol 1988; 6: 337-342.

22. Muriel P. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 1998; 56: 773-79.

23. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-36.

24. Cruz L, Castañeda-Hernández G, Navarrete A. Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. Can J Physiol Pharmacol 1999; 77: 441-6.

25. Nakajima M, Inoue T, Kuroiwa Y. Cytochrome P450 2C9 catalyzes Indomethacin ï-demethylacion in human liver microsomas. Drug Metabolism and Disposition. 1997; 26(3): 261-67.